Bayer chief eyes $2.6B in Xarelto sales

Bayer CEO Werner Wenning predicted that the market for new blood thinners could reach $12 billion to $15 billion, with his company's drug Xarelto--now awaiting U.S. approval--accounting for some $2.6 billion of that. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.